Table 2.
Reslizumab: main randomized clinical trials.
| Authors | Inclusion criteria | N | Main results |
|---|---|---|---|
| Kips et al. (2003) | Severe asthmatics | 18 | ↓ Blood and sputum eosinophils Transient FEV1 increase |
| Castro et al. (2011) | Poorly controlled eosinophilic asthma | 61 | ↓ Blood and sputum eosinophils ↑ FEV1, ↑ FVC ACQ-5 improvement |
| Castro et al. (2015) | Severe eosinophilic asthma | 953 | ↓ Blood eosinophils ↑ FEV1 ↓ Exacerbations AQLQ, ACQ-7, ASUI improvement |
| Bjermer et al. (2016) | Severe eosinophilic asthma | 315 | ↓ Blood eosinophils ↑ FEV1, ↑ FEF25–75 ACQ-5, ACQ-6, AQLQ, ASUI improvement |
| Brusselle et al. (2017) | Severe eosinophilic asthma | 477 | ↓ Exacerbations ↑ FEV1 |
FEV1, Forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, Peak expiratory flow; ACQ, Asthma control questionnaire; AQLQ, Asthma quality of life questionnaire; ASUI, Asthma symptom utility index; FEF25–75, forced expiratory flow at 25–75% of forced vital capacity.